Skip to main content

Table 2 BRAFV600E and BRAFWT cell lines used for detailed analysis.

From: Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations

Cell Line BRAF/NRAS Cell line characteristics
M249 BRAFV600E Single agent vemurafenib: Highly sensitive
Single agent metformin: Highly sensitive
Combination: Slight synergy
M249-AR4 BRAFV600E
NRASQ61K 		Single agent vemurafenib: Resistant
Single agent metformin: Intermediate sensitive
Combination: Antagonistic
M263 BRAFV600E Single agent vemurafenib: Resistant
Single agent metformin: Intermediate sensitive
Combination: Slight synergy
M308 BRAFV600E Single agent vemurafenib: Resistant
Single agent metformin: Highly sensitive
Combination: Antagonistic
SKMEL28 BRAFV600E Single agent vemurafenib: Intermediate sensitive
Single agent metformin: Resistant
Combination: Antagonistic
M207 NRASQ61L Single agent vemurafenib: Resistant
Single agent metformin: Resistant
Combination: Slight synergy
M296 NRASQ61L Single agent vemurafenib: Resistant
Single agent metformin: Highly sensitive
Combination: Slight synergy
SKMEL173 NRASQ61K Single agent vemurafenib: Resistant
Single agent metformin: Resistant
Combination: Highly antagonistic
WM1366 NRAS Single agent vemurafenib: Resistant
Single agent metformin: Highly sensitive
Combination: Slight synergy
M257 Wild type Single agent vemurafenib: Resistant
Single agent metformin: Intermediate sensitive
Combination: Slight synergy
  1. Legend: Sensitivity to single agent vemurafenib: highly sensitive if IC50 < 1 μM; intermediate sensitive with IC50 1-10 μM; resistant if IC50 > 10 μM. Sensitivity to single agent metformin: highly sensitive if IC50 < 10 mM; intermediate sensitive with IC50 10-20 mM; resistant if IC50 > 20 mM. Sensitivity to the combination of vemurafenib and metformin: CI > 1 antagonistic; CI 1-0.3 slight synergy; CI < 0.3 strong synergy.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us